12 Oct WisBusiness: UW-Madison researchers study psilocybin-based drug by Tryp Therapeutics
Two UW-Madison researchers will be conducting a clinical study on a psilocybin-based drug being developed by a Canadian pharmaceutical company.
Psilocybin is the psychoactive component of so-called “magic mushrooms,” which scientists around the world are studying as a potential method for treating mental health issues such as depression and anxiety. Tryp Therapeutics is developing its psilocybin product for chronic pain conditions such as fibromyalgia and phantom limb pain, as well as other diseases, a release shows.
The company recently announced the partnership with Paul Hutson, a professor with the university’s School of Pharmacy, and Christopher Nicholas, an assistant professor with the UW School of Medicine and Public Health. Hutson is also the founding director of the Transdisciplinary Center for Research in Psychoactive Substances at UW-Madison.
The two researchers will lead a clinical pharmacology study of the company’s drug product called TRP-8803. It will focus on safety and how the drug interacts with the body in “healthy, volunteer patients.”
Nicholas will contribute to the study’s design including measuring outcomes and psychological support for participants. In a release, Hutson notes that psilocybin-based treatments have “incredible clinical potential.”
“Our collaboration will explore important safety and dosing considerations with the potential to create a best-in-class psychedelic therapy with significant benefits to patients across a wide range of indications,” he said.
See a recent story on the Transdisciplinary Center for Research in Psychoactive Substances: https://www.wisbusiness.com/2021/new-center-for-research-on-psychoactive-substances-to-build-on-existing-momentum/
See the release: https://www.newsfilecorp.com/release/98790